TW201819630A - Non-obese diabetes mice and its applications - Google Patents

Abstract

The invention relates to a novel non-obese diabetic (NOD) mouse and its application. Particularly, the invention relates to a NOD mouse specifically expressing anti-polyethylene glycol membrane antibody reporter (anti-PEG reporter) in the NOD mouse.

Description

 Non-obese diabetic mice and their applications  

The present invention relates to novel non-obese diabetic (NOD) mice and uses thereof. In particular, the present invention relates to NOD mice which specifically express an anti-polyethylene glycol membrane antibody reporter gene (anti-PEG reporter gene) in NOD mice.

It has been reported that transgenic mice develop diabetes at rates similar to or higher than wild-type controls and kinetics. Transgenic mice can be used in the study of diabetes and pancreatic beta islet cell biology. NOD mice were used as an animal model of type 1 diabetes. NOD mice exhibit sensitivity to spontaneous autoimmune insulin-dependent diabetes mellitus (IDDM). The loci associated with the sensitivity of IDDM have been identified in NOD mouse strains by the development of homologous allogeneic mouse strains that have identified several insulin dependent diabetes (Idd) loci. In view of the fact that NOD mice have unique genetic factors and pathological mechanisms similar to human type 1 diabetes, NOD mice explored the IDDM mechanism and important animal models for evaluating various therapeutic strategies.

However, in order to explore whether apoptosis progresses in pancreatic β-cells (insulinitis), multiple NOD mice should be sacrificed to obtain a series of islet slices at consecutive time points. Therefore, the study could not continuously observe the pathological process in one mouse and use the method of monitoring the blood glucose of NOD mice to assess the progression of diabetes; only advanced diabetes can be measured. In addition, the incidence of spontaneous diabetes in NOD mice is 60-80% in females and 20-30% in males. The onset of diabetes is also different between males and females: it usually lasts for several weeks in males. Therefore, changes in animal gender and environmental and experimental conditions will affect the results of diabetes research. For example, NOD.Cg-Tg(Ins1-EGFP)1Hara/QtngJ (also known as: MIP-GFP (line 1), NOD.B6-MIP-GFP) is a homozygous homology to the MIP-GFP transgene. In an allogeneic NOD mouse, the MIP-GFP transgene has EGFP fluorescence in tissues in which insulin I is normally detected, particularly in pancreatic β-cells. However, this NOD transgenic mouse can only be used in an optical imaging system and observation of diabetes can be performed only after the rats are sacrificed. In addition, when the islets of NOD mice were transplanted to normal mice, GFP derived from sea lice can cause immune rejection. US 8,507,207 provides a reporter gene system and, in particular, a method for monitoring the presence and distribution of genes and cells using a recombinant nucleotide sequence encoding an anti-polyethylene glycol recombinant single-stranded membrane antibody as a reporter gene.

However, there is a need to develop NOD mice that can be used to continuously observe the progression of diabetes and to evaluate the drug treatment of type I diabetes.

The presence of reporter genes in islets of non-obese diabetic mice (NOD mice) allows researchers to monitor islet loss by a non-invasive imaging system, overcoming the traditional method in which researchers need to sacrifice a large number of NOD mice to observe islet sections. The defect of islet inflammation. The present invention successfully developed NOD/pIns-α PEG mice stably expressing an anti-PEG reporter gene in their islets by using an insulin promoter. The PEG-NIR797 fluorescent probe specifically accumulates in the islet regions of NOD/pIns-α PEG mice, but not in control NOD mice, assisting researchers in the process of easily and accurately tracing islet loss by optical imaging systems, and further Study the islet protective effects of drugs or genes. Importantly, the expression of anti-PEG reporter genes in the islets of NOD/pIns-α PEG mice did not affect islet size, insulin secretion, and disease progression in type 1 diabetes. NOD/pIns-α PEG mice help researchers easily track disease progression in type 1 diabetes with a non-invasive imaging system, further providing valuable tools for pharmaceutical companies and drug research companies worldwide to screen and evaluate diabetes drug.

The invention provides a transgenic construct encoding an anti-PEG reporter gene comprising a polynucleotide comprising a nucleotide sequence having SEQ ID NO: 1 or a substantially identical nucleoside thereof from the 5' to 3' sequence a human insulin promoter having an acid sequence, a first exon of a human insulin gene having the nucleotide sequence of SEQ ID NO: 2 or a substantially identical nucleotide sequence thereof, having the nucleotide sequence of SEQ ID NO: Or a first intron of a human insulin gene having substantially the same nucleotide sequence, a second exon of a human insulin gene having the nucleotide sequence of SEQ ID NO: 4 or a substantially identical nucleotide sequence thereof a second intron of a rabbit beta globin gene having the nucleotide sequence of SEQ ID NO: 5 or a substantially identical nucleotide sequence thereof, having the nucleotide sequence of SEQ ID NO: 6 or a An anti-PEG reporter gene of the same nucleotide sequence and a third intron of the rabbit beta globin gene having SEQ ID NO: 7 or a substantially identical nucleotide sequence thereof, operably linked to each other.

The invention also provides vectors comprising the transgenic constructs of the invention or cells comprising the vectors mentioned above.

The invention also provides chimeric NOD mice, wherein the genome of the NOD mouse comprises a transgenic construct of the invention that is incorporated into the locus of the mouse chromosome 11. In one embodiment, the site is chr11:14970958 of chromosome 11 of the mouse.

The invention also provides a variety of applications, including screening for candidate agents or gene therapies for treating or preventing type 1 diabetes using the chimeric NOD mice of the invention, and screening for candidate agents or genes that are resistant to islet transplant rejection.

Figure 1 shows a schematic representation of the complete transgenic construct of the present invention. The complete transgene from the 5' to 3' sequence includes the human insulin promoter, the first exon of the human insulin gene, the first intron of the human insulin gene, the second exon of the human insulin gene, and the rabbit β-globulin. The second intron of the gene, the anti-PEG reporter gene (from the 5' to 3' sequence including the immunoglobulin signal peptide, the VL-Ck fragment of the anti-PEG antibody AGP3, the internal ribosome entry site, the immunoglobulin signal peptide, The VH-CH1 fragment of the anti-PEG antibody AGP3 and the C-shaped extracellular-transmembrane-cytoplasmic domain of the murine B7-1 antigen) and the third intron of the rabbit β-globin gene.

Figure 2 A and B show the in vitro performance and function of the pIns-anti-PEG reporter gene. The anti-PEG reporter gene was transferred to a plastid having a human insulin promoter to construct a pIns-anti-PEG plastid (control group CMV promoter-anti-PEG plastid). The gene was transferred to (A) murine islet beta cells (NIT-1) or (B) murine fibroblasts (3T3). The performance and function of the anti-PEG reporter gene in the two cells was detected by PEG-quantum dots.

Figure 3 shows the results of a genotyping PCR assay for identifying NOD/pIns-α PEG mice. The genotyping primer (forward) is designed to bind to the second intron of the human insulin gene. The genotyping primer (reverse) was designed to bind to the VL-CK fragment of the anti-PEG reporter gene. By using the PCR method in combination with the genotyping primers, it can be used in NOD/pIns-α PEG mice (No. 354, No. 353, No. 352, No. 258) and not in wild-type NOD mice (347 No., No. 349) A DNA fragment having an expected size of 845 bp was produced.

Figure 4 shows the insertion site of the transgenic construct in the genome of NOD/pIns-α PEG mice. The transgenic construct of the present invention is incorporated into the locus of mouse chromosome 11. In one embodiment, the site is chr11:14970958 of chromosome 11 of the mouse.

Figure 5 shows the results of a site-directed PCR assay for identifying the insertion site of the pIns-αPEG gene in NOD/pIns-α PEG mice. The localization primer (forward) was designed to bind to chromosome 11 of the NOD mouse. The localization primer (reverse) is designed to bind to the human insulin promoter. By using the PCR method in combination with the positioning primers, it can be used in NOD/pIns-α PEG mice (No. 354, No. 353, No. 352, No. 258) and not in wild-type NOD mice (No. 347, A DNA fragment of about 650 bp in size is produced in No. 349).

Figure 6 A and B show the performance of anti-PEG reporter genes and their proteins in NOD/pIns-α PEG mice. The pIns-αPEG gene was transferred into the embryo of NOD/ShiLtJ mice by microinjection technique (embryonic line from Jackson Laboratory, stock number: 001976) to generate NOD/pIns-α PEG mice. (A) Identification and screening of transgenic mice expressing anti-PEG reporter genes by genotyping PCR. (B) Analysis of NOD/pIns-α PEG mouse progeny (F0) numbered 4-1, 5-2, and 5-4 to observe whether the islets stably express the protein against the PEG reporter gene; obtain the islet cells of the transgenic mouse The goat anti-mouse IgM Fc antibody was used to subject it to western blot analysis (the anti-PEG reporter gene was constructed by murine IgM antibody).

Figure 7 shows the in vivo function of the pIns-anti-PEG reporter gene (in islet cells of NOD/pIns-α PEG mice). Islet cells were obtained from NOD/pIns-α PEG mice (progeny of transgenic mice numbered 5-2) or 5-week old NOD mice. The binding ability of islet cells to PEG probes was observed using a PEG-FITC fluorescent probe and a fluorescence microscope.

Figure 8 shows a comparison of differences on PEG- ¹³¹ I accumulation in pancreatic NOD / pIns-αPEG of murine or in the NOD mice. The PEG- ¹³¹ I radioactive probe was intravenously injected into NOD/pIns-α PEG mice (n=3) or NOD mice (n=3), and their pancreas was obtained after 24 hours and 48 hours, respectively. The gamma counter was used to detect the radioactivity value of the area around the pancreas.

Figure 9 shows optical imaging of the pancreas of NOD/pIns-α PEG mice. 4-arm PEG-NIR797 (5 μg/20 μL/mouse) was injected into NOD/pIns-α PEG mice or NOD mice by pancreatic injection. After 24 hours, the specific fluorescent signal of the anti-PEG reporter gene around the pancreatic region was detected by a 3D in vivo imaging system (IVIS 200).

Figures 10A to C show the survival rate of islets of NOD/pIns-α PEG mice detected by non-invasive imaging. 4-arm PEG-NIR797 (50 μg/100 μL/mouse) was injected intraperitoneally into healthy NOD mice (10 weeks old, as a negative control, left side) and in NOD/pIns-α PEG mice (10 weeks old, right) . After 24 hours in the dark, the survival rate of islets in the pancreas of NOD/pIns-α PEG mice was observed by a 3D in vivo imaging system (IVIS 200). (A) Results of non-invasive imaging. (B) The peritoneal cavity of NOD mice and NOD/pIns-α PEG mice was opened and the accumulation of 4-arm PEG-NIR797 therein was evaluated. (C) Results of imaging of 4-arm PEG-NIR797 in the pancreas of NOD mice and NOD/pIns-α PEG mice.

Figure 11 A and B show apoptosis of islets of NOD/pIns-α PEG mice by non-invasive imaging. (A) 4-arm PEG-NIR797 (50 μg/100 μL/mouse) was injected into NOD/pIns-α PEG mice every two weeks after 9 weeks of age. After 24 hours in the dark, the apoptosis process of islets of NOD/pIns-α PEG mice of different ages was observed by a 3D in vivo imaging system (IVIS 200). (B) Fluorescence signals of the islets of NOD/pIns-α PEG mice at 9, 13 and 17 weeks old were measured and quantified values are shown as bars in the figure. In addition, in order to evaluate whether the apoptosis process of the islets of NOD/pIns-α PEG mice displayed by the imaging system is related to the ability to metabolize glucose (the weaker the fluorescent signal in islets, the worse the ability to metabolize glucose/blood sugar), 1.5 g/kg/BW of glucose was orally administered to NOD/pIns-α PEG mice that had been fasted for 8 hours. One hour after the administration, blood was obtained from the tail of the mouse and blood glucose concentration was measured. Hyperglycemic concentrations represent insufficient insulin secretion (ie, insufficient number of islets), which may represent the severity of type I diabetes.

Figures 12A and B show the comparison of islet size and number in wild-type NOD mice and NOD/pIns-α PEG mice. Pancreatic tissues of wild type NOD mice and NOD/pIns-α PEG mice (n=5) at 10 weeks of age were collected. (A) Pancreatic tissue was stained by H&E staining and compared to islets of wild-type NOD mice and NOD/pIns-α PEG mice. (B) Measure the average size of islets. (C) Measure the average number of islets. Bar: SD.

Figure 13 A and B show immune cell infiltration of islets in wild-type NOD mice and NOD/pIns-α PEG mice. Pancreatic tissues of wild-type NOD mice and NOD/pIns-α PEG mice (n=5) at 20 weeks of age were collected. (A) Pancreatic tissue was stained by H&E staining. The difference of immune cell infiltration between islets in wild-type NOD mice and NOD/pIns-α PEG mice was observed. Arrows with solid lines indicate islets, and arrows with dashed lines indicate immune cells. (B) Quantification of islet immune cell infiltration.

Figure 14 shows the ability of NOD/pIns-α PEG mouse islet β cells to secrete insulin. Wild-type NOD mice and NOD/pIns-α PEG mice (n=5) were fasted for 8 hours, and 1.5 g/kg/BW of glucose was orally administered to mice. Blood was obtained from the tail of the mouse at 0, 30, 60, 90, and 120 minutes after administration and blood glucose concentration was measured to evaluate whether the anti-PEG reporter gene expressed on the cell membrane of islet β cells could affect insulin secretion. . Bar: SD.

Figure 15 A and B show the incidence of diabetes and anti-insulin autoantibody responses in NOD/pIns-α PEG and NOD mice. (A) Blood glucose levels of NOD/pIns-α PEG mice (n=20) and NOD mice (n=20) were monitored weekly after 5 weeks of birth; if the measured blood glucose exceeded 200 mg/L for two consecutive weeks, then It was determined as the incidence of diabetes. (B) Blood of NOD/pIns-α PEG mice (n=10) and NOD mice (n=10) were obtained weekly after 5 weeks of birth; whether anti-GAD65 autologous was produced in the blood by anti-GAD65 ELISA kit antibody.

The present invention provides non-obese diabetic mice and their use in non-invasive imaging of islet loss processes therein.

Unless otherwise indicated, terms as used herein have the meaning commonly used in scientific proverbs, and may be different from spoken language idioms.

Genes should be interpreted broadly to include both transcribed and non-transcribed regions.

With respect to a given nucleic acid, "encoding" or "encoded" means including information translated into a specified protein. The nucleic acid encoding the protein may comprise non-translated sequences (eg, introns) within the translational region of the nucleic acid, or may be devoid of such intervening non-translated sequences (eg, as in cDNA). The information by which the protein is encoded is explained in detail by using a codon.

The term "transgenic rodent" as used herein is intended to include a murine wherein one or more of the cells contain a heterologous nucleic acid encoding an anti-PEG reporter gene. Heterologous nucleic acids are introduced into rodents by human intervention, for example, by transgenic techniques well known in the art. Preferably, the heterologous nucleic acid is integrated into the chromosome of the cell.

The term "transgenic" as used herein refers to a nucleic acid sequence encoding an anti-PEG reporter gene.

The term "nucleic acid" as used herein includes reference to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, encompasses A single-stranded nucleic acid hybridizes to a known analog having the essential properties of a natural nucleotide.

The term "degenerate sequence" as used herein refers to a sequence having the degeneracy of a codon (which is the redundancy of the genetic code), manifested as the multiplicity of the three base pair codon combinations of the specified amino acids. The degeneracy of the genetic code explains the existence of synonymous mutations.

The term "promoter" as used herein refers to a DNA sequence which, when attached to a nucleotide sequence of interest, is capable of controlling the transcription of a nucleotide sequence of interest into mRNA.

The term "operably linked" as used herein, refers to DNA sequences and regulatory sequences that are linked such that the genes are allowed to behave in the manner in which the appropriate molecule (eg, a transcriptional activator protein) binds to the regulatory sequence.

The term "transgenic construct" as used herein refers to a nucleic acid molecule, such as a vector, containing a target gene (e.g., an anti-PEG reporter gene transgene) operably linked in a manner that expresses a gene in a host cell. The term "nucleic acid" as used herein refers to polynucleotides such as deoxyribonucleic acid (DNA) and, if appropriate, ribonucleic acid (RNA). The term as used herein also encompasses analogs of RNA or DNA made from nucleotide analogs, and as applicable to the examples, single-stranded (eg, sense or antisense) and double-stranded polynucleotides.

The term "recombinant vector" as used herein, which describes a vector which expresses a protein or RNA of interest in a suitable host cell, refers to the genetic construction of a regulatory element comprising a gene insert operably linked in such a manner as to be expressed in a host cell. body.

The term "transcriptional regulatory sequence" as used herein refers to a DNA sequence, such as a initiation signal, an enhancer, and a promoter that induces or controls the transcription of a protein coding sequence to which it is operably linked.

The term "chimeric" as used herein (eg, "chimeric animal" or "chimeric pancreas") is intended to describe an organ or animal comprising a heterologous genetic tissue or cell.

The term "candidate agent" as used herein is intended to include synthetic, natural or recombinantly produced molecules (eg, small molecules; drugs; peptides; antibodies (including antigen-binding antibody fragments) or other immunotherapeutic agents; present in eukaryotic or prokaryotic Endogenous factors (eg, polypeptides, plant extracts, and the like) in cells, etc.). Particularly concerned are screening tests for agents that have low toxicity to human cells.

In one aspect, the invention provides a transgenic construct encoding an anti-PEG reporter gene comprising a polynucleotide comprising a nucleotide sequence having SEQ ID NO: 1 from a 5' to 3' sequence or a human insulin promoter of substantially the same nucleotide sequence, a first exon of a human insulin gene having the nucleotide sequence of SEQ ID NO: 2 or a substantially identical nucleotide sequence thereof, having SEQ ID NO a first intron of a human insulin gene having a nucleotide sequence of 3 or a substantially identical nucleotide sequence thereof, having the nucleotide sequence of SEQ ID NO: 4 or a substantially identical nucleotide sequence thereof a second intron of the human insulin gene, a second intron of the rabbit beta globin gene having the nucleotide sequence of SEQ ID NO: 5 or a substantially identical nucleotide sequence thereof, having SEQ ID NO: 6 An anti-PEG reporter gene having a nucleotide sequence or a substantially identical nucleotide sequence thereof and a third intron of a rabbit beta globin gene having SEQ ID NO: 7 or a substantially identical nucleotide sequence thereof, They are operatively connected to each other.

The transgenic construct of the present invention comprises a human insulin promoter (1620 bp), a first exon (partial human insulin gene, 42 bp), a first intron (human insulin gene, 178 bp), and a second exon ( Part of the human insulin gene, 50 bp), second intron (rabbit beta globin gene, 573 bp), anti-PEG reporter gene and third intron (rabbit beta globin gene, 449 bp).

In one embodiment, the anti-PEG reporter gene comprises the nucleotide gene of SEQ ID NO: 6.

In one embodiment, substantially identical nucleotide sequences are degenerate sequences.

The sequences of human insulin promoter, first exon, first intron, second exon, second intron, anti-PEG reporter gene and third intron are listed below.

Human insulin promoter (1620 bp) (SEQ ID NO: 1)

First exon (partial human insulin gene, 42 bp)

Agccctccaggacaggctgcatcagaagaggccatcaagcag (SEQ ID NO: 2)

First intron (human insulin gene, 178 bp) (SEQ ID NO: 3)

Second exon (partial human insulin gene, 50bp)

Atcactgtccttctgcacctgcagggatcggggatcctgagaacttcagg (SEQ ID NO: 4)

Second intron (rabbit beta globin gene, 573 bp) (SEQ ID NO: 5)

anti-PEG reporter gene (2574 bp) (SEQ ID NO: 6)

Third intron (rabbit beta globin gene, 449 bp) (SEQ ID NO: 7)

The term "substantially identical nucleotide sequence" as used herein refers to DNA that is sufficiently homologous to a reference polynucleotide such that it will be in a strictly stringent or higher stringency hybridization condition with a reference nucleotide. Hybrid. A DNA having a "substantially identical nucleotide sequence" to a reference nucleotide sequence can have a identity in the range of at least 60% to at least 95% relative to a reference nucleotide sequence.

Moderately stringent hybridization refers to conditions that allow a target nucleic acid to bind to a complementary nucleic acid. The hybridized nucleic acid will typically have a identity ranging from at least about 60% to at least about 95%. Moderately stringent conditions are equivalent to hybridization in 50% formamide, 5 x Denhart solution, 5 x saline sodium EDTA buffer (SSPE), 0.2% SDS (Aldrich) at about 42 ° C, followed by about 42 The conditions of washing in 0.2 SSPE, 0.2% SDS (Aldrich) at °C. Highly stringent hybridization refers to conditions that allow hybridization of only the nucleic acid sequences that form stable hybrids in 0.018 M NaCl at about 65 °C, for example, if the hybrid is unstable at 0.015 M NaCl at about 65 °C, It will be unstable under highly stringent conditions, as contemplated herein. Highly stringent conditions can be achieved, for example, by hybridization in 50% formamide, 5 x Denhart's solution, 5 x SSPE, 0.2% SDS at about 42 ° C, followed by 0.1 x SSPE and 0.1% SDS at about 65 °C. Provided by washing.

The anti-PEG reporter gene is constructed according to "Kuo-Hsing Chuang et al., The Journal of Nuclear medicine, 2010, Vol. 51, No. 6, pp. 933-941". The anti-PEG reporter gene consists of a Fab fragment of the murine anti-PEG monoclonal antibody AGP3 fused to the C-shaped extracellular-transmembrane-cytoplasmic domain of the murine B7-1 receptor.

The transgenic construction system of the present invention is constructed according to general selection techniques. The first non-coding exon, followed by the first intron and the second non-coding exon of 50 bp were saved to ensure the stringency of the insulin promoter. The intron of the rabbit β-globin gene is introduced adjacent to the second exon. The forward primer in the second intron of the rabbit beta globin gene and the reverse primer in the coding region of the VL-CK fragment of the anti-PEG reporter gene were designed to determine the transcription of the transgene in RT PCR and from the PCR The presence of the anti-PEG reporter gene transgene was detected. Only anti-PEG reporter genes can express anti-PEG reporter gene proteins.

If desired, the transgenic constructs of the invention can be engineered to be operably linked to appropriate expression elements, such as enhancers, to permit expression of the genetic elements in DNA constructs in appropriate cells or tissues. The use of performance control mechanisms allows for targeted delivery and expression of target genes. For example, a construct of the present invention can be constructed using a display cassette comprising a transcriptional and translational initiation region associated with gene expression in a tissue in the 5'-3' transcriptional direction, encoding an anti-PEG reporter gene. DNA and transcriptional and translational termination regions that function in host animals. The transcriptional initiation region can be endogenous to the host animal or foreign or foreign to the host animal. The transgenic constructs described herein can be incorporated into vectors for propagation or transfection into appropriate cells for production.

In another aspect, the invention provides a vector comprising a transgenic construct of the invention or a cell comprising the vector mentioned above.

The vector may contain regulatory elements that provide tissue-specific or inducible expression of the operably linked nucleic acid. Appropriate enhancers that allow expression of the anti-PEG reporter gene in the desired genome can be readily determined by those skilled in the art.

For example, a transgenic construct comprising an anti-PEG reporter gene is selected into a vector by general selection techniques to form a pIns-α PEG plastid having a polynucleotide encoding a human insulin promoter; for example, see pLNCX- eB7 retroviral vector; for example, see "Kuo-Hsiang Chuang et al, The Journal of Nuclear Medicine, 2010, Vol. 51, No. 6, pp. 933-941"; for example, pIns vector; for example, see "Hsiang -Hsuan Sung et al., The Journal of Experimental Medicine, 2004, Vol. 199, No. 8, pp. 1143-1151.

In another aspect, the invention provides a chimeric NOD mouse, wherein the genetic construct of the NOD mouse comprises a transgenic construct of the invention. In one embodiment, the transgenic construct of the invention is incorporated into the locus of chromosome 11 of the mouse. In one embodiment, the transgenic construct of the invention is incorporated into the site of mouse chromosome 11 chr11: 14970958.

The transgenic construct can be integrated into the genome of the transgenic NOD mouse by any method known to those skilled in the art. The transgenic construct can be introduced into a pluripotent cell, such as an ES cell, by any means that will allow the introduced molecule to undergo recombination in its homologous region. Techniques that may be used include, but are not limited to, calcium phosphate/DNA coprecipitation, microinjection of DNA into the nucleus, electroporation, fusion of bacterial protoplasts with intact cells, transfection, and polycations (eg, polybrene, poly Amino acid, etc.).

For example, zygote is a well-known method for microinjection and a method of microinjecting zygotes is well known. The vector containing the transgenic construct is microinjected into the fertilized egg using a microinjection technique known in the art to produce a NOD/pIns-α PEG mouse; for example, see Marjeta Grzech et al, Molecular and Cellular Endocrinology, 315 (2010), Pp. 219-224.

Specifically, transgenic mice were generated by digesting pIns-αPEG plastids with Nsi I and Not I enzymes. The fragment containing the human insulin promoter, the anti-PEG reporter gene and the polyadenylation signal is then gel purified. Transgenic mice were generated by injection of a standard pronucleus into mouse embryos. Briefly, during pre-nuclear microinjection, the anti-PEG reporter gene cassette DNA was introduced directly into the mouse egg after just fertilization. Typically, after one or two cell divisions have taken place, DNA tends to integrate as a number of tandem arrays at random locations in the genome. Therefore, the resulting mice were only partially transgenic. If the transgenic cells contribute to the germ cell line, some transgenic eggs or sperm will be produced and the next generation of mice will be transgenic.

In another aspect, the invention provides a method for determining the effect of a target gene on apoptosis of islet cells in a NOD mouse of the invention, the method comprising: hybridizing a NOD mouse of the invention with a NOD transgenic mouse carrying a target gene; The first time point detects the signal emitted by the NOD transgenic mouse; the dose of the PEG-imaging agent is administered to the NOD mouse; and the change in the signal emitted by the NOD mouse is determined at subsequent time points; wherein if the signal is emitted by the NOD mouse The change is significantly different from the signal emitted at the first time point, and the effect of the gene on apoptosis of islet cells is determined.

Transgenic mice expressing anti-PEG reporter genes were generated. In these animals, the reporter gene (anti-PEG reporter gene) is ligated to the human insulin promoter, thereby driving the expression of the anti-PEG reporter gene in islet cells. Systemic injection of PEG imaging agents produces detectable and quantifiable signals from live mice. This model successfully quantifies the islet cell apoptosis.

Advances in detector technology have led to significant improvements in sensitivity and imaging quality. The PEG-imaging agent can be PEG-NIR797, PEG-SPIO or PEG-124I. Signal detection can be optical imaging, MRI or micro PET.

Among the available imaging modalities, bioluminescence or fluorescence based optical technology has emerged as the most accessible and easy to operate. Bioluminescence imaging (BLI) is characterized by extremely high sensitivity due to the extremely low background illumination (noise) from the tissue.

Monitoring of the performance of the performance cassette using non-invasive intact animal imaging has been described (Contag, P. et al, Nature Medicine 4(2): 245-247, 1998). This imaging typically uses at least one photodetector device component, such as a charge coupled device (CCD) camera.

In another aspect, the invention provides a method of screening for a candidate agent or gene therapy for treating or preventing type 1 diabetes comprising administering a candidate agent or gene to a NOD mouse of the invention; imaging PEG- at different time points The dose of the agent is administered to the NOD mouse; and the signal emitted by the NOD mouse is measured at different time points; wherein the signal emitted by the NOD mouse is unchanged or increases with time relative to the candidate drug prior to administration, indicating that the candidate agent or gene has a pair The effect of treatment or prevention of type 1 diabetes.

In another aspect, the invention provides a method of screening for a candidate agent or gene that is resistant to islet transplant rejection, comprising transplanting an islet obtained from a NOD mouse of the invention into a recipient mouse, and administering a candidate agent or gene resistant to rejection Accepting the mice; administering the dose of the PEG-imaging agent to the NOD mice at different time points; and measuring the signals emitted by the NOD mice at different time points; wherein the signal emitted by the NOD mouse is unchanged relative to the signal before the candidate agent is administered Or increasing over time indicates that the candidate agent or gene has an effect against graft rejection.

The NOD mice of the invention can be used in a variety of other screening assays. For example, any of a variety of candidate agents suspected of treating or preventing type 1 diabetes, as well as appropriate antagonists and blocking therapeutic agents, or candidate agents or genes that are resistant to islet transplant rejection, can be administered to NOD mice and evaluated. Screened by the effect of the agent.

Candidate agents encompass a wide variety of chemical types, but are typically organic molecules, preferably small organic compounds. Candidate agents are also found in biomolecules including, but not limited to, peptides, sugars, fatty acids, steroids, purines, pyrimidines, derivatives thereof, structural analogs or combinations thereof.

Candidate agents are obtained from a variety of sources, including libraries of synthetic or natural compounds. For example, a variety of means can be used to randomly or directionally synthesize a wide variety of organic compounds and biomolecules, including the expression of randomized oligonucleotides and oligopeptides. In addition, natural or synthetically produced libraries and compounds are readily modified by conventional chemical, physical, and biochemical means and can be used to create combinatorial libraries.

The candidate agent can be administered in any desired and/or suitable manner for delivering the agent to affect the desired result. For example, a candidate agent can be administered by injection (eg, by intravenous, intramuscular, subcutaneous, or direct injection into the tissue in which the desired effect is to be achieved), orally, or by any other desired means. . In general, in vivo screening will involve a number of animals that receive different amounts and concentrations of candidate agents (from no agent to an amount of agent that is close to the upper limit of the amount that can be successfully delivered to the animal), and the in vivo screening can include Formulations and routes of delivery of the agent. The agents may be administered alone or in combination of two or more agents, especially when a combination of administration agents produces a synergistic effect.

In yet another aspect, the invention provides a method of assessing survival of transplanted islets comprising transplanting islets obtained from a NOD mouse of the invention into a recipient mouse, administering the dose of the PEG-imaging agent at different time points NOD mice; and signals emitted by NOD mice at different time points; wherein if the signal emitted by the NOD mouse decreases over time, the survival of the transplanted islets is poor.

Based on the use of or in addition to the NOD rats of the present invention described above, it will be readily apparent to those skilled in the art after reading this disclosure.

The following examples are presented to fully disclose and explain how to make and use the present invention, and the examples are not intended to limit the scope of the invention to the inventor, and are not intended to represent all of the The only experiment.

Instance Example 1 Preparation of the transgenic construct of the present invention

To construct the pIns-anti-PEG reporter gene as shown in Figure 1, the VL-Ck and VH-CH1 genes of the anti-PEG reporter gene were ligated by the internal ribosome entry site (IRES) and fused to the murine B7.1 antigen. The complementary DNA sequence of the C-shaped extracellular-transmembrane-cytoplasmic domain of (B7) to form an anti-PEG reporter gene. The anti-PEG reporter gene was sectioned and ligated into a vector having a human insulin promoter to construct a pIns-αPEG plastid. Figure 1 shows a schematic representation of the complete transgenic construct of the present invention.

Example 2 Evaluation of Specificity of the Invention in Murine Pancreatic β Cells

To assess whether a functional anti-PEG reporter gene can specifically express on murine pancreatic beta cells, the pIns-alpha PEG plastid was transfected into murine islet beta cells (NIT-1) or murine fibroblasts (3T3). The functional anti-PEG reporter gene can be specifically expressed on murine islet β cells (NIT-1) under the regulation of the human insulin promoter using a PEG (PEG-Qdot) modified fluorescent probe (Fig. 2A). At the same time, it cannot be specifically expressed on murine fibroblasts (3T3) (see Figure 2B).

Example 3 Preparation of NOD/pIns-α PEG mouse of the present invention

To construct a NOD mouse (NOD/pIns-α PEG mouse) with islet cells that specifically express an anti-PEG reporter gene, the pIns-αPEG plastid was digested with Nsi 1 and Not 1 enzymes to isolate the pIns-αPEG gene fragment, and then used. Microinjection technique The pIns-αPEG gene fragment was transfected into fertilized eggs of NOD mice to produce NOD/pIns-α PEG mice (F0).

Genotyping assays were used to determine that the NOD mice carry the pIns-alpha PEG gene. The genetic DNA of NOD mice was isolated by a simple tissue and cell genetic DNA purification kit (GeneMark DP021E). The 2D Taq PCR Mix Red reagent (Bioman, RT803R) was used by PCR technology to determine the NOD mouse carrying pIns-αPEG using the following targeting primers, namely the forward primer 5'-TCATGCCTTCTTCTCTTTCCTACAG-3 and the reverse primer 5'-TCGTTTTGCTCGCTCGAGACACTC-3. gene. The PCR conditions are shown as follows: (1) preliminary denaturation: 3 minutes at 94 ° C; (2) gene amplification (repeated 35 cycles), a. denaturation: 30 seconds at 94 ° C, b. fit: at 62 ° C For the next 30 seconds, c. extension: 60 seconds at 72 ° C; (3) final extension: 10 minutes at 72 ° C; (4) storage at 4 ° C. Only NOD/pIns-α PEG mice had a 850 bp PCR product, whereas wild-type NOD mice did not. Figure 3 shows that NOD/pIns-α PEG mice have a 850 bp PCR product.

The position of the transgenic construct of Example 1 inserted into the NOD murine genome was determined using a positional PCR assay. The genetic DNA of NOD mice was isolated by a simple tissue and cell genetic DNA purification kit (GeneMark DP021E). The SuperIn PCR mixed mother liquor reagent (2×) (TOOLS TE-SR01) was used to determine pIns-αPEG using the following positioning primers, ie, the forward primer 5'-CCCAATATTCTGGGTTCCAGGATGAAAG-3 and the reverse primer 5'-CATGGGTGCCTCCTTGAGAGG-3. The gene was localized to the chr11:14970958 site of chromosome 11 of the NOD mouse (see Figure 5). The PCR conditions are shown as follows: (1) preliminary denaturation: 2 minutes at 95 ° C; (2) gene amplification (repeated 35 cycles), a. denaturation: 35 seconds at 95 ° C, b. fit: at 55 ° C For the next 35 seconds, c. extension: 2.5 minutes at 72 ° C; (3) final extension: 10 minutes at 72 ° C; (4) storage at 4 ° C. The PCR results showed that the NOD/pIns-α PEG mouse had a 650 bp PCT product, so it was confirmed that the pIns-αPEG gene was inserted into the chromosome 11 of the NOD mouse (chr11: 14970958). The insertion site of the transgenic construct in the genome of the NOD mouse is shown in Figure 4.

After genotypic analysis, it was shown that NOD transgenic mice carried an anti-PEG reporter gene (Fig. 6A). In addition, the islet cells of the NOD/pIns-α PEG mouse progeny stably expressed the anti-PEG reporter gene protein by Western blot analysis (see FIG. 6B). The above results show that the anti-PEG reporter gene of F0 transgenic mice can be successfully inherited to the offspring.

Fluorescence microscopy was further used to demonstrate that the PEG-FITC fluorescent probe specifically binds to the islet cells of NOD/pIns-α PEG mice, rather than the control NOD mice (see Figure 7). The degree of anti-PEG reporter gene expression of three NOD/pIns-α PEG mice was detected using PEG- ¹³¹ I and gamma counters. The results showed that the radiation value of the pancreas of NOD/pIns-α PEG mice was 1.96 times and 2.48 times that of the control NOD mice at 24 hours and 48 hours after administration of PEG- ¹³¹ I to the mice (see Fig. 8).

Example 4 Specific binding of PEG-imaging agent to islet cells expressing anti-PEG reporter gene

To test whether PEG-imaging agents can specifically bind to islet cells expressing anti-PEG reporter genes, the fluorescent imaging agent 4-arm PEG-NIR797 was injected separately into NOD/pIns-α PEG mice with type 1 diabetes (T1D). And in the pancreas of NOD/pIns-α PEG mice without T1D. After 24 hours, apoptosis of islet cells was assessed using an optical imaging system (IVIS200 optical imaging system). Figure 9 shows that 4-arm PEG-NIR797 imaging agent can specifically accumulate in NOD/pIns-α PEG mice without T1D, while it cannot accumulate in NOD/pIns-α PEG mice with T1D. Furthermore, since wild-type NOD mice do not exhibit an anti-PEG reporter gene, 4-arm PEG-NIR797 imaging agent is not accumulated in islet cells.

It was further demonstrated that 4-arm NIR797 imaging agent accumulated only in healthy islet cells of NOD/pIns-α PEG mice after intraperitoneal injection of 4-arm NIR797 imaging agent into healthy NOD/pIns-α PEG mice and wild-type NOD mice. It did not accumulate in wild-type NOD mice (see Figure 10). Finally, it was demonstrated that intraperitoneal injection of 4-arm NIR797 imaging agent in combination with an optical imaging system accurately and continuously traces apoptosis progression in islets of NOD/pIns-α PEG mice over different weeks (see Figure 11A), and is emitted from islets. The intensity of the fluorescent signal is highly correlated with the progression of T1D (see Figure 11B).

Example 5 Evaluation of Physiological Characteristics and Pathological Characteristics of Islet Based on NOD/pIns-αPEG

To assess whether the physiological and pathological features of the islets of NOD/pIns-α PEG were affected by the anti-PEG reporter gene expression, histochemical staining analysis was performed. The morphology of the islets of NOD/pIns-α PEG mice (see Figure 12A), size (see Figure 12B) and number (see Figure 8C) were demonstrated to be indistinguishable from those of control NOD mice. There was no difference in immune cell infiltration of islets between 20-week-old NOD/pIns-α PEG mice and control NOD mice (see Figure 13). The glucose metabolism rate of NOD/pIns-αPEG mice was similar to that of control NOD mice (see Figure 14). Furthermore, the T1D progression of NOD/pIns-α PEG mice (see Figure 15A) and the onset of the immune response against insulin antibodies (see Figure 15B) were identical to those of the control NOD mice.

<110> Taipei Medical University

<120> Non-obese diabetic mice and their applications

<130> T54267/US5866

<160> 7

<170> PatentIn version 3.5

<210> 1

<211> 1620

<212> DNA

<213> Human

<220>

<221> misc_feature

<222> (601)..(601)

<223> n is a, c, g or t

<220>

<221> misc_feature

<222> (607)..(607)

<223> n is a, c, g or t

<220>

<221> misc_feature

<222> (610)..(610)

<223> n is a, c, g or t

<220>

<221> misc_feature

<222> (617)..(617)

<223> n is a, c, g or t

<220>

<221> misc_feature

<222> (646)..(646)

<223> n is a, c, g or t

<220>

<221> misc_feature

<222> (666)..(666)

<223> n is a, c, g or t

<220>

<221> misc_feature

<222> (679)..(679)

<223> n is a, c, g or t

<220>

<221> misc_feature

<222> (695)..(695)

<223> n is a, c, g or t

<220>

<221> misc_feature

<222> (708)..(708)

<223> n is a, c, g or t

<220>

<221> misc_feature

<222> (1054)..(1054)

<223> n is a, c, g or t

<400> 1

<210> 2

<211> 42

<212> DNA

<213> Human

<400> 2

<210> 3

<211> 178

<212> DNA

<213> Human

<400> 3

<210> 4

<211> 50

<212> DNA

<213> Human

<400> 4

<210> 5

<211> 573

<212> DNA

<213> Rabbit

<400> 5

<210> 6

<211> 2574

<212> DNA

<213> Labor

<220>

<223> Anti-PEG reporter gene

<400> 6

<210> 7

<211> 449

<212> DNA

<213> Rabbit

<400> 7

Claims (14)

 A transgenic construct encoding an anti-PEG reporter gene comprising a polynucleotide comprising a nucleotide sequence having SEQ ID NO: 1 or a substantially identical nucleotide sequence thereof from a 5' to 3' sequence a human insulin promoter, a first exon of a human insulin gene having the nucleotide sequence of SEQ ID NO: 2 or a substantially identical nucleotide sequence thereof, having the nucleotide sequence of SEQ ID NO: 3 or a first intron of a human insulin gene having substantially the same nucleotide sequence, a second exon of a human insulin gene having the nucleotide sequence of SEQ ID NO: 4 or a substantially identical nucleotide sequence thereof a second intron of a rabbit beta globin gene having the nucleotide sequence of SEQ ID NO: 5 or a substantially identical nucleotide sequence thereof, having the nucleotide sequence of SEQ ID NO: 6 or a An anti-PEG reporter gene of the same nucleotide sequence and a third intron of the rabbit beta globin gene having SEQ ID NO: 7 or a substantially identical nucleotide sequence thereof, operably linked to each other.    The transgenic construct of claim 1, wherein the substantially identical nucleotide sequence is a degenerate sequence.    A vector comprising the transgenic construct of claim 1.    A cell comprising the vector of claim 3.    A chimeric NOD mouse, wherein the NOD mouse genome comprises the transgenic construct of claim 1.    A chimeric NOD mouse according to claim 5, wherein the transgenic construct is incorporated into the chromosome 11 of the mouse.    A chimeric NOD mouse according to claim 6, wherein the transgenic construct is incorporated into the site of chromosome 11 chr11: 14970958.    A method of producing a chimeric NOD mouse according to claim 5, comprising the steps of: 1) preparing a vector comprising the transgenic construct of claim 1 as claimed in claim 2, and transfecting the fertilized egg of the NOD mouse with the vector .    A method for determining the effect of a target gene on apoptosis of islet cells in a chimeric NOD mouse of claim 5, the method comprising: hybridizing a NOD mouse of claim 5 with a NOD transgenic mouse carrying the target gene; A signal emitted by the NOD transgenic mouse is detected at a time point; a dose of the PEG-imaging agent is administered to the NOD mouse; and a change in the signal emitted by the NOD mouse is determined at subsequent time points; wherein the NOD mouse is The change in the signal of the emission is significantly different from the signal emitted at the first time point, and the effect of the gene on apoptosis of the islet cells is determined.   The method according to item 9 of the request, wherein the imaging agent based PEG- PEG-NIR797, PEG-SPIO or PEG- ¹²⁴ I.  The method of claim 9, wherein the signal detection is optical imaging, MRI or microPET.    A method of screening for a candidate agent or gene therapy for treating or preventing type 1 diabetes, comprising administering a candidate agent or gene to a chimeric NOD mouse as claimed in claim 5; and administering the dose of the PEG-imaging agent at different time points And the NOD mouse; and the signal emitted by the NOD mouse at different time points; wherein the signal emitted by the NOD mouse is unchanged or increased with time relative to the candidate drug prior to administration indicating that the candidate agent or gene has The effect of treatment and prevention of type 1 diabetes.    A method for screening a candidate agent or gene for resistance to islet transplant rejection, comprising transplanting an islet obtained from a chimeric NOD mouse of claim 5 to a recipient mouse, and administering a candidate drug or gene resistant to rejection to the recipient mouse; - the dose of the imaging agent is administered to the NOD mouse at different time points; and the signal emitted by the NOD mouse is measured at different time points; wherein the signal emitted by the NOD mouse is unchanged from the signal prior to administration of the candidate agent Or increasing over time indicates that the candidate agent or gene has an effect against graft rejection.    A method for assessing survival of transplanted islets comprising transplanting islets from a chimeric NOD mouse of claim 5 to a recipient mouse, administering a dose of the PEG-imaging agent to the NOD mouse at different time points; The signal emitted by the NOD mouse is measured at a time point; wherein if the signal emitted by the NOD mouse decreases over time, the survival of the transplanted islets is poor.